Argenica Therapeutics

AGN.AX

Biotechnology · Healthcare

Exchange

Australian Securities Exchange

Winston Score

Winston is worried

Below-average fundamentals — multiple weak pillars.

Based on the IPO prospectus (annual filing). This score will refine automatically once the company reports its first quarters.

Data as of Aug 9, 2026 · filings through Dec 31, 2025

Argenica Therapeutics is a small Australian biotechnology company focused on developing drugs to treat brain injuries caused by strokes. Its lead drug candidate, ARG-007, is a peptide designed to protect brain cells from dying after a stroke occurs. The company is in the clinical-stage, meaning it does not yet sell any products and is still running trials to test whether its treatments are safe and effective.

Argenica makes no revenue from product sales yet. It funds its research through capital raises, grants, and government incentives, which is typical for early-stage biotech companies. Based in Perth, Australia, it is a very small company with a market cap near zero, and it has no approved products or commercial moat at this stage. The key risk is that ARG-007 could fail in clinical trials, which would severely threaten the company's future, while success in later-stage trials would be the main catalyst for growth.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+54.7% YoY

YoY Growth Rate

Strong revenue growth

EPS Growth

-22.8% YoY

YoY Growth Rate

Earnings declining

Insider Activity

24.6%ownership

Insiders own a meaningful stake in the company

Cash Runway

~7 months

$11M cash & investments

Short runway — potential dilution ahead through share issuance

Strong grower

Argenica Therapeutics is growing revenue at 55% year-over-year. The Winston Score penalises unprofitable companies, but revenue at this pace tells a different story — this is a company still in "build mode."

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

100.0%

Premium pricing power — 100.0% gross margin

Operating Margin

-239.1%

Losing money on operations — -239.1%

ROCE

-106.2%

Weak — -106.2% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

+23.7%

Fast-growing sales (+23.7% YoY)

EPS YoY

N/A

—

Data not available

EPS Consistency

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

-177.5%

Burning cash (-177.5%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.00

Conservative — low debt load (0.00)

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial